Safe Cardioversion for Patients With Acute-Onset Atrial Fibrillation and Flutter: Practical Concerns and...

Area of Science:

• Cardiology
• Emergency Medicine
• Clinical Guidelines

Background:

• The Canadian Cardiovascular Society (CCS) released an updated guideline in 2018 for atrial fibrillation management.
• Recommendations 2 and 6 of the update have raised concerns among Canadian emergency physicians.
• These recommendations impact the management of patients undergoing cardioversion.

Purpose of the Study:

• To discuss concerns raised by Canadian emergency physicians regarding specific CCS 2018 atrial fibrillation guidelines.
• To analyze the implications of recommendations that narrow the window for safe cardioversion.
• To evaluate the impact of mandating 4 weeks of anticoagulation for all urgent cardioversions, irrespective of CHADS-65 score.

Main Methods:

• Viewpoint discussion analyzing clinical practice implications.
• Review of specific recommendations (2 and 6) from the CCS 2018 atrial fibrillation update.
• Consideration of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework.

Main Results:

• The updated CCS guidelines may restrict the safe window for cardioversion.
• A proposed 4-week anticoagulation period for all urgent cardioversions is discussed.
• Concerns exist regarding the basis of these recommendations on low-quality evidence.

Conclusions:

• The current recommendations may lead to suboptimal patient care in emergency settings.
• The implications of applying weak recommendations derived from low-quality evidence require careful consideration.
• Further evidence is needed to support the proposed changes in atrial fibrillation management during cardioversion.